ALX ONCOLOGY HLD. DL-,001

ALX Oncology reported Q1 2026 EPS of -0.17, exceeding the estimate of -0.19 (surprise 10.53%). After the release the share price rose as much as 11.23%, while it traded slightly lower in pre-market trading. The company secured solid financing through a successful funding round and plans to advance its lead programs, particularly Evorpacept and ALX2004, toward key clinical milestones. ALX expects to initiate a regulatory‑relevant study by the end of 2026 and sees sufficient funds for the next 12–18 months. » Plus sur de.investing.com

ALX Oncology reports Q1 2026 results with adjusted EPS of -$0.17 and a completed financing of $150 million, raising cash to $169.1 million as of March 31 and extending runway to mid-2028. In the presented cohort, Evorpacept combined with zanidatamab achieved an objective response rate of 100% (5/5) in centrally confirmed HER2-positive, CD47-high breast cancer, with median duration of response of 20.2 months and median PFS of 22.1 months. CD47 overexpression has been validated as a predictive biomarker in two independent studies (including ASPEN-06); the Phase 2 study ASPEN-09 continues to recruit, with topline data expected mid-2027. ALX also highlights progress in the EGFR-ADC program ALX2004 (Phase 1) and sees significant commercial potential with addressable patient numbers and market size estimates of $2–4 billion. » Plus sur de.investing.com

ALX Oncology presented data at the ESMO congress on the combination of Evorpacept plus Zanidatamab in a phase‑1b/2 study in 24 female patients with metastatic HER2‑positive breast cancer. In the cohort with high CD47 expression (>20%), all five evaluable patients achieved a confirmed objective response rate of 100%, with a median progression‑free survival of 22.1 months and a median duration of response of 20.2 months; the overall response rate across all patients was 33% (median PFS 3.6 months). ALX shares have risen sharply recently; based on the data the company has a market capitalization of USD 281 million and more cash than debt. Analysts see further upside potential with price targets between USD 4 and USD 6. » Plus sur de.investing.com